SLPI and ovarian cancer: In ovarian cancer, secretory leukocyte protease inhibitor (SLPI) protein derived from FAPhigh α-SMAlow CAFs can be encapsulated in extracellular vesicles (EVs) and delivered to cancer cells, promoting cell proliferation, adhesion, invasion, and migration via the PI3K/AKT signaling pathway [13].